Literature DB >> 26981604

Molecular Mechanisms of Chemoresistance in Oral Cancer.

Cheng Wang, Xi Qiang Liu, Jin Song Hou, Jian Ning Wang, Hong Zhang Huang.   

Abstract

Oral cancer is an aggressive disease with the propensity for local recurrence and distal metastasis in the head and neck region. Currently, cisplatin-based chemotherapy or concurrent radiochemotherapy is still the first choice to treat the advanced stage cancers, in particular, the unresectable tumours. Unfortunately, innate and acquired resistance to chemotherapy agent greatly limited its effectiveness and often led to treatment failure in these patients. Hence, it is urgent to clarify the mechanisms underlying the development of chemoresistance in patients with oral cancer. In this article, the current understandings on molecular mechanisms of chemoresistance in oral cancer were reviewed, including drug efflux, apoptosis, DNA damage and repair, epithelial mesenchymal transition, autophagy and miRNA.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26981604     DOI: 10.3290/j.cjdr.a35694

Source DB:  PubMed          Journal:  Chin J Dent Res        ISSN: 1462-6446


  17 in total

1.  Downregulation of SELENBP1 enhances oral squamous cell carcinoma chemoresistance through KEAP1-NRF2 signaling.

Authors:  Hui Zeng; Xubing Zhao; Chengfang Tang
Journal:  Cancer Chemother Pharmacol       Date:  2021-04-27       Impact factor: 3.333

Review 2.  Research progress and clinical application prospects of miRNAs in oral cancer.

Authors:  Long Xing; Zhenghu Feng; Hongbing Nie; Meitian Liu; Yali Liu; Xiaohua Zhang; Haijing Zhou
Journal:  Mol Biol Rep       Date:  2022-06-20       Impact factor: 2.316

3.  Analysis of the subcellular location of lncRNA SLC16A1-AS1 and its interaction with premature miR-5088-5p in oral squamous cell carcinoma.

Authors:  Tiecheng Li; Di Wang; Shuo Yang
Journal:  Odontology       Date:  2022-07-12       Impact factor: 2.885

4.  MicroRNA-485-5p targets keratin 17 to regulate oral cancer stemness and chemoresistance via the integrin/FAK/Src/ERK/β-catenin pathway.

Authors:  Te-Hsuan Jang; Wei-Chieh Huang; Shiao-Lin Tung; Sheng-Chieh Lin; Po-Ming Chen; Chun-Yu Cho; Ya-Yu Yang; Tzu-Chen Yen; Guo-Hsuen Lo; Shuang-En Chuang; Lu-Hai Wang
Journal:  J Biomed Sci       Date:  2022-06-15       Impact factor: 12.771

Review 5.  The Microenvironment of Tongue Cancer.

Authors:  Want Tao; Zeng Li-Juan; Li Kan; Li Jing-Yuan; Liu Xiang-Qi; Liang Yu-Jie
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

6.  RRBP1 rewires cisplatin resistance in oral squamous cell carcinoma by regulating Hippo pathway.

Authors:  Omprakash Shriwas; Rakesh Arya; Sibasish Mohanty; Pallavi Mohapatra; Sugandh Kumar; Rachna Rath; Sandeep Rai Kaushik; Falak Pahwa; Krushna Chandra Murmu; Saroj Kumar Das Majumdar; Dillip Kumar Muduly; Anshuman Dixit; Punit Prasad; Ranjan K Nanda; Rupesh Dash
Journal:  Br J Cancer       Date:  2021-03-24       Impact factor: 7.640

7.  MicroRNA-218 promotes cisplatin resistance in oral cancer via the PPP2R5A/Wnt signaling pathway.

Authors:  Zehang Zhuang; Fengchun Hu; Jing Hu; Cheng Wang; Jinsong Hou; Zhiqiang Yu; Tony T Wang; Xiqiang Liu; Hongzhang Huang
Journal:  Oncol Rep       Date:  2017-08-11       Impact factor: 3.906

8.  MicroRNA-143 suppresses oral squamous cell carcinoma cell growth, invasion and glucose metabolism through targeting hexokinase 2.

Authors:  Xianghui Sun; Lei Zhang
Journal:  Biosci Rep       Date:  2017-06-08       Impact factor: 3.840

9.  Periostin secreted by cancer-associated fibroblasts promotes cancer stemness in head and neck cancer by activating protein tyrosine kinase 7.

Authors:  Binbin Yu; Kailiu Wu; Xu Wang; Jianjun Zhang; Lizhen Wang; Yingying Jiang; Xueqin Zhu; Wantao Chen; Ming Yan
Journal:  Cell Death Dis       Date:  2018-10-22       Impact factor: 8.469

10.  Synergistic inhibitory effects of cetuximab and curcumin on human cisplatin-resistant oral cancer CAR cells through intrinsic apoptotic process.

Authors:  Chin-Fu Chen; Chi-Cheng Lu; Jo-Hua Chiang; Hong-Yi Chiu; Jai-Sing Yang; Chao-Ying Lee; Tzong-Der Way; Hao-Jen Huang
Journal:  Oncol Lett       Date:  2018-09-07       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.